Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA and Arsenic Trioxide for Newly Diagnosed APL
NCT00413166Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2006
- Primary completion
- Feb 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of arsenic trioxide and tretinoin in acute promyelocytic leukemia (APL), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2006; status: completed.
02
Drugs
arsenic trioxidetretinoin
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00413166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00413166.